Philips introduces fully integrated echocardiography experience, bringing together new transducer technology, AI-driven automated measurements and remote access at EuroEcho 2021

Rhea-AI Summary

Philips (NYSE: PHG) has unveiled its next-generation nSIGHT Plus imaging architecture and X5-1c Transthoracic Transducer aimed at enhancing cardiac imaging performance. Key innovations include the AI-driven Auto Measure application, which cuts echo quantification time by 51%, and Collaboration Live for remote access during exams. These advancements support clinicians in improving diagnostic confidence and workflow efficiency, particularly during the EuroEcho 2021 Virtual Congress.

Positive

• Introduction of nSIGHT Plus imaging architecture enhancing cardiac imaging.
• X5-1c Transthoracic Transducer increases access to imaging windows.
• AI-enhanced Auto Measure application reduces echo measurement time by 51%.
• Collaboration Live solution facilitates remote diagnostic access during exams.
• 80% of patients report improved diagnostic confidence with new transducer.

Negative

• None.

December 9, 2021

• Philips’ next-generation nSIGHT Plus imaging architecture and new X5-1c Transthoracic Transducer drive breakthrough cardiac imaging performance
• Debut of AI-enhanced Auto Measure application helps reduce echo quantification time, improving patient and staff experience
• New remote access with diagnostic confidence on Collaboration Live solution extends the reach and efficiency of ultrasound teams

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today expanded its ultrasound portfolio with new robust imaging tools and features for Cardiology to increase diagnostic confidence and workflow efficiency. During its participation in the EuroEcho 2021 Virtual Congress, taking place December 9-11, Philips will showcase how its cardiac ultrasound solutions support cardiology patients and clinicians, from early detection, diagnosis and treatment, through ongoing assessment and long-term follow-up.

Integrated systems and informatics enable efficiency and diagnostic confidence
Philips brings together the latest release of the EPIQ CVx and Affiniti CVx ultrasound platforms, automated analysis, Collaboration Live remote diagnosis and Cardiovascular Workspace – IntelliSpace Cardiovascular – end-to-end workflow, for a fully integrated experience in echocardiography. Advanced technology is helping to foster first-time-right diagnosis and timely treatment. Philips nSIGHT Plus is a proprietary imaging architecture that touches all aspects of image acquisition and processing, creating images with optimal resolution down to the pixel level, in contrast with conventional systems that form the image line by line. In addition, the new Philips X5-1c transducer facilitates easier access to imaging windows between the ribs.

Clinician feedback showed that diagnostic confidence in 3D left ventricular function quantification was improved in 80% of patients undergoing transthoracic echo (TTE) exams using the X5-1c transducer [1]. Philips’ AI-enhanced Auto Measure application delivers fast and consistent measurements in half the time of manual methods. Using Auto Measure on Philips EPIQ CVx and Affiniti CVx ultrasound systems can reduce the time for standard 2D echo measurements by 51% [2]. Auto Measure AI and AutoStrain Left Atrium (LA) and Right Ventricle (RV) are now available across the Philips CVx portfolio.

Enabling remote access and limiting risk of COVID-19 exposure, Philips echocardiography suite also includes Collaboration Live, an integrated tele-ultrasound solution providing remote access to clinical staff in real-time during exams.

“With echocardiography the first imaging modality utilized for a greater volume of patients [3], clinicians are relying on ultrasound to provide care more than ever before,” said Jeff Cohen, General Manager of Ultrasound at Philips. “Cardiac imaging workflows need to be streamlined at every step to address the volume and complexity of cases. Philips echocardiography provides a connected ecosystem of integrated workflow solutions for cardiology. Combined with advanced diagnostic tools, our integrated solutions deliver clear insights on the patient’s condition quickly. These recent introductions also reinforce how our ultrasound capabilities bring strong clinical value to areas outside of echocardiography, including liver disease management, to help improve decision support and care at each step in the patient journey.”  

“Imaging performance is the most important attribute to allow me to be confident in my diagnosis and treatment planning,” said Dr. Roberto Lang, Director, Noninvasive Cardiac Imaging Laboratory, University of Chicago. During the European Society of Cardiology virtual symposium, “Transthoracic echo like you’ve never seen before,” Dr. Lang explains how the new X5-1c echo transducer and AI-enhanced quantification are designed to improve clinical confidence in everyday patient care.

Delivering better heart care with greater efficiency and clinical confidence
Philips Ultrasound System – EPIQ CVx – and Ultrasound System – Affiniti  CVx – provide a suite of features that can help reduce exam times, from the echo lab to the patient bedside, all while providing the confidence clinicians need to help enhance decision-making to inform the best treatment plan.

EuroEcho registrants are invited to join the Philips satellite symposium, “Using the latest innovations in Echocardiography to improve patient care,” on December 10, featuring  Professors Denisa Muraru, Teresa Lopez Fernandez, and Manuel Barreiro Perez and hosted by Professor Bernard Cosyns.

For more information on Philips’ latest innovative technology across its portfolio of cardiology ultrasound solutions, visit the Philips echocardiography page.

[1] Based on Philips external testing as compared to X5-1 transducer.
[2] Based on Philips external testing as compared to manual measurement methods. 
[3] Reeves RA, Halpern EJ, Rao VM. Cardiac Imaging Trends from 2010 to 2019 in the Medicare Population. Radiology: Cardiothoracic Imaging. 2021 Sep 30; 3(5):e210156.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: + 1 978 221 8919
E-mail: kathy.oreilly@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips X5 -1c Transthoracic Transducer in use
• Philips X5 -1c Transthoracic Transducer

FAQ

What are the benefits of Philips' new X5-1c Transducer?

The X5-1c Transducer improves access to imaging windows and enhances diagnostic confidence in 80% of patients during transthoracic echo exams.

How much time can Philips' Auto Measure application save?

Philips' Auto Measure application can reduce echo quantification time by 51% compared to manual methods.

What is the purpose of the Collaboration Live solution?

The Collaboration Live solution allows remote access to clinical staff during ultrasound exams, enhancing efficiency and safety.

Where was Philips' new technology showcased?

Philips showcased its new technology at the EuroEcho 2021 Virtual Congress from December 9-11.

What is the impact of Philips' innovations on cardiac imaging?

Philips' innovations improve diagnostic confidence and streamline workflows, which are critical for effective patient care in cardiology.